Pleomorphic xanthoastrocytoma of the spinal cord: Case report and literature review

Clinical Neuropathology

Volumn 33, Issue 3, 2014, Pages 190-196

  Das, Sumit ^a   Yip, Stephen ^b   Hukin, Juliette ^c   Cochrane, Douglas ^a   Dunham, Christopher ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

BRAF V600E; Pediatrics; Pleomorphic xanthoastrocytoma; Spinal cord

Indexed keywords

B RAF KINASE; GADOLINIUM; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2;

ADOLESCENT; ARTICLE; CANCER GRADING; CANCER SURGERY; CASE REPORT; CONTRAST ENHANCEMENT; DISEASE DURATION; DORSAL ROOT; FOLLOW UP; GAIT DISORDER; GENE MUTATION; HEAD MOVEMENT; HUMAN; HUMAN TISSUE; LIMB WEAKNESS; MALE; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; NECK PAIN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PLEOMORPHIC XANTHOASTROCYTOMA; PRIORITY JOURNAL; SHOULDER PAIN; SPINAL ARACHNOID; SPINAL CORD PLEOMORPHIC XANTHOASTROCYTOMA; SPINAL CORD TUMOR; TUMOR GROWTH;

ADOLESCENT; ASTROCYTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; PROTO-ONCOGENE PROTEINS B-RAF; SPINAL CORD NEOPLASMS;

EID: 84899649978     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300689     Document Type: Article

References (21)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. IARC: Lyon; 2007.
2. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS ONE. 2011; 6: e17948.
3. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121: 397-405.
4. Kepes JJ, Rubinstein LJ, Eng LF. Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. Cancer. 1979; 44: 1839-1852.
5. Rao AA, Laack NN, Giannini C, Wetmore C. Pleomorphic xanthoastrocytoma in children and adolescents. Pediatr Blood Cancer. 2010; 55: 290-294.
6. Fouladi M, Jenkins J, Burger P, Langston J, Merchant T, Heideman R, Thompson S, Sanford A, Kun L, Gajjar A. Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. Neuro-oncol. 2001; 3: 184-192.
7. Gill M, Pathak HC, Madan R, Bhattacharya S, Choudhary GS. Primary spinal pleomorphic xanthoastrocytoma. Neurol India. 2010; 58: 771-773.
8. Herpers MJ, Freling G, Beuls EA. Pleomorphic xanthoastrocytoma in the spinal cord. Case report. J Neurosurg. 1994; 80: 564-569.
9. Nakamura M, Chiba K, Matsumoto M, Ikeda E, Toyama Y. Pleomorphic xanthoastrocytoma of the spinal cord. Case report. J Neurosurg Spine. 2006; 5: 72-75.
10. Simal-Julián JA, Sanchis-Martín R, Prat-Acín R, Miranda-Lloret P, Conde-Sardón R, Cárdenas-Ruiz-Valdepeñas E, Beltrán-Giner A. [Spinal pleomorphic xantoastrocytoma. Case report]. Neurocirugia (Astur). 2010; 21: 390-395.
11. Richter A, Grieu F, Carrello A, Amanuel B, Namdarian K, Rynska A, Lucas A, Michael V, Bell A, Fox SB, Hewitt CA, Do H, McArthur GA, Wong SQ, Dobrovic A, Iacopetta B. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep. 2013; 3: 1659.
12. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012; 226: 7-16.
13. Hardison HH, Packer RJ, Rorke LB, Schut L, Sutton LN, Bruce DA. Outcome of children with primary intramedullary spinal cord tumors. Childs Nerv Syst. 1987; 3: 89-92.
14. Nadkarni TD, Rekate HL. Pediatric intramedullary spinal cord tumors. Critical review of the literature. Childs Nerv Syst. 1999; 15: 17-28.
15. Stiller CA, Nectoux J. International incidence of childhood brain and spinal tumours. Int J Epidemiol. 1994; 23: 458-464.
16. Wilson PE, Oleszek JL, Clayton GH. Pediatric spinal cord tumors and masses. J Spinal Cord Med. 2007; 30 (Suppl 1): S15-S20.
17. Miller DC. Surgical pathology of intramedullary spinal cord neoplasms. J Neurooncol. 2000; 47: 189-194.
18. Ellezam B, Theeler BJ, Walbert T, Mammoser AG, Horbinski C, Kleinschmidt-DeMasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JM, Aldape KD. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathol. 2012; 124: 449-451.
19. Horbinski C. To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol. 2013; 72: 2-7.
20. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, Thomas M, Vagner S, Favre M, Tomasic G, Wechsler J, Lacroix L, Robert C. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013; 24: 1691-1697.
21. Chamberlain MC. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol. 2013; 114: 237-240.